|
|
|
Insider
Information: |
Secora Michael |
Relationship: |
Chief Financial Officer |
City: |
Salt Lake City |
State: |
UT |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
1,402,131 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$10,053,279 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
1,402,131 |
|
|
Total
Value |
$10,053,279 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
|
|
Stock
price went down : |
|
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Recursion Pharmaceuticals, Inc. |
RXRX |
Chief Financial Officer |
2024-09-11 |
1,402,131 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
82 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-08-16 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
888,186 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-08-16 |
4 |
AS |
$8.90 |
$222,518 |
D/D |
(25,000) |
863,186 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-09-12 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
900,686 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-09-12 |
4 |
AS |
$8.43 |
$210,633 |
D/D |
(25,000) |
875,686 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-09-13 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
913,186 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-09-13 |
4 |
AS |
$8.69 |
$217,318 |
D/D |
(25,000) |
888,186 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-10-10 |
4 |
AS |
$7.07 |
$176,763 |
D/D |
(25,000) |
900,686 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-10-10 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
925,686 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-10-11 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
938,186 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-10-11 |
4 |
AS |
$6.85 |
$171,313 |
D/D |
(25,000) |
913,186 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-11-14 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
950,686 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-11-14 |
4 |
AS |
$6.32 |
$157,943 |
D/D |
(25,000) |
925,686 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-11-15 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
963,186 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-11-15 |
4 |
AS |
$7.25 |
$182,986 |
D/D |
(25,000) |
938,186 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-11-15 |
4 |
D |
$7.18 |
$51,495 |
D/D |
(7,172) |
931,014 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-12-12 |
4 |
AS |
$7.39 |
$184,868 |
D/D |
(25,000) |
943,514 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-12-12 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
968,514 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-12-13 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
981,014 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2023-12-13 |
4 |
AS |
$7.59 |
$189,770 |
D/D |
(25,000) |
956,014 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-01-16 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
993,514 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-01-16 |
4 |
AS |
$10.45 |
$261,160 |
D/D |
(25,000) |
968,514 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-01-17 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,006,014 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-01-17 |
4 |
AS |
$10.25 |
$256,348 |
D/D |
(25,000) |
981,014 |
0 |
% |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
182,849 |
1,163,863 |
0 |
- |
|
RXRX |
Recursion Pharmaceuticals... |
Chief Financial Officer |
|
2024-02-09 |
4 |
D |
$10.09 |
$25,346 |
D/D |
(2,512) |
1,161,351 |
0 |
- |
|
82 Records found
|
|
Page 2 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|